Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle
Proceedings of the National Academy of Sciences · 10.01.2023 · 120 (2)
DOI: 10.1073/pnas.2206324120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.01.2023. Verfasst von Adrien Morin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Evolution of Neuromuscular Diseases - Innovative Concepts and Practice (END-ICAP) U1179, Université Paris-Saclay, Université de Versailles Saint-Quen…. Hauptthemen laut MEDLINE: Dystrophin, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Association Monegasque contre les Myopathies, Association Francaise contre les Myopathies, Universite Franco-Allemande.
Abstract (Originalsprache)
Dystrophin is essential for muscle health: its sarcolemmal absence causes the fatal, X-linked condition, Duchenne muscular dystrophy (DMD). However, its normal, spatial organization remains poorly understood, which hinders the interpretation of efficacy of its therapeutic restoration. Using female reporter mice heterozygous for fluorescently tagged dystrophin ( Dmd EGFP ), we here reveal that dystrophin distribution is unexpectedly compartmentalized, being restricted to myonuclear-defined sarcolemmal territories extending ~80 µm, which we called “basal sarcolemmal dystrophin units (BSDUs).” These territories were further specialized at myotendinous junctions, where both Dmd transcripts and dystrophin protein were enriched. Genome-level correction in X-linked muscular dystrophy mice via CRISPR/Cas9 gene editing restored a mosaic of separated dystrophin domains, whereas transcript-level Dmd correction, following treatment with tricyclo-DNA antisense oligonucleotides, restored dystrophin initially at junctions before extending along the entire fiber—with levels ~2% sufficient to moderate the dystrophic process. We conclude that widespread restoration of fiber dystrophin is likely critical for therapeutic success in DMD, perhaps most importantly, at muscle–tendon junctions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Evolution of Neuromuscular Diseases - Innovative Concepts and Practice (END-ICAP) U1179, Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm, 78000 Versailles, France.
- Department of Clinical Science and Services, Comparative Neuromuscular Diseases Laboratory, Royal Veterinary College, London NW1 0TU, United Kingdom.
- SQY Therapeutics, 78180 Montigny-le-Bretonneux, France.
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
- Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
- Berlin Institute of Health, 10117 Berlin, Germany.
ORCID-Profile: Adrien Morin, Amalia Stantzou, John Hildyard, Meriem Matouk, Isabelle Richard, Tudor Manoliu, Aurélie Goyenvalle, Sestina Falcone, Markus Schuelke, Corinne Laplace-Builhé, Richard J Piercy, Helge Amthor
Förderung
- Association Monegasque contre les Myopathies
- Association Francaise contre les Myopathies
- Universite Franco-Allemande
- Agence Nationale de la Recherche
Zitieren
APA
Morin, A., Stantzou, A., Petrova, O. N., Hildyard, J., Tensorer, T., Matouk, M., Petkova, M. V., Richard, I., Manoliu, T., Goyenvalle, A., Falcone, S., Schuelke, M., Laplace-Builhé, C., Piercy, R. J., Garcia, L., & Amthor, H. (2023). Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle. Proceedings of the National Academy of Sciences, 120(2). https://doi.org/10.1073/pnas.2206324120
Vancouver
Morin A, Stantzou A, Petrova ON, Hildyard J, Tensorer T, Matouk M, et al. Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle. Proceedings of the National Academy of Sciences. 2023;120(2). doi:10.1073/pnas.2206324120
BibTeX
@article{Morin2023,
author = {Morin, Adrien and Stantzou, Amalia and Petrova, Olga N and Hildyard, John and Tensorer, Thomas and Matouk, Meriem and Petkova, Mina V and Richard, Isabelle and Manoliu, Tudor and Goyenvalle, Aurélie and Falcone, Sestina and Schuelke, Markus and Laplace-Builhé, Corinne and Piercy, Richard J and Garcia, Luis and Amthor, Helge},
title = {Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {2},
doi = {10.1073/pnas.2206324120}
}
EUVIMED